Current Atherosclerosis Reports

, Volume 12, Issue 5, pp 316–321

Current and Future Use of Intravenous Thrombolysis for Acute Ischemic Stroke


DOI: 10.1007/s11883-010-0121-8

Cite this article as:
Elijovich, L. & Chong, J.Y. Curr Atheroscler Rep (2010) 12: 316. doi:10.1007/s11883-010-0121-8


Stroke is a common and disabling condition. Intravenous tissue plasminogen activator (tPA) administered within 3 h of symptom onset is the standard therapy for eligible patients with acute ischemic stroke. Unfortunately, because of the time limitation, very few patients with ischemic stroke actually receive this treatment. In order to increase the number of patients who may benefit from acute treatment, recent research has focused on expanding the time window for thrombolysis and improving its efficacy to ultimately improve patient outcome.


Acute ischemic stroke Thrombolysis Endovascular treatment tPA 

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.St. Luke’s Roosevelt Hospital CenterNew YorkUSA
  2. 2.St. Luke’s Roosevelt Hospital CenterNew YorkUSA

Personalised recommendations